Tikosyn

Manufacturing · 11-50 Employees

View Company Info for Free

Overview

Revenue

<$5 Million

Industry

Manufacturing Pharmaceuticals
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1

About Tikosyn

Increase in QT interval is directly related to dofetilide dose and plasma concentration. Figure 1 shows that the relationship in normal volunteers between dofetilide plasma concentrations and change in QTc is linear, with a positive slope of approximately 1525 msec/(ng/mL) after the first dose and approximately 1015 msec/(ng/mL) at Day 23 (reflecting a steady state of dosing). A linear relationship between mean QTc increase and dofetilide dose was also seen in patients with renal impairment, in patients with ischemic heart disease, and in patients with supraventricular and ventricular arrhythmias. Note: The range of dofetilide plasma concentrations achieved with the 500 mcg BID dose adjusted for creatinine clearance is 13.5 ng/mL. The relationship between dose, efficacy, and the increase in QTc from baseline at steady state for the two randomized, placebo-controlled studies (described further below) is shown in Figure 2. The studies examined the effectiveness of TIKOSYN in conversion tRead more
Popular SearchesTikosynPfizer IncTIKOSYN ®( dofetilideSIC Code 28,283NAICS Code 32,325Show more

Is Tikosyn your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Compare Similar Companies to Tikosyn

Compare insights from companies similar to Tikosyn, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

Tikosyn

<$5M
11-50
Private
-
-
N/A
<$5M
11-50
Private
-
2018
N/A
<$5M
11-50
Private
-
-
N/A
<$5M
11-50
Private
-
1960
TM
Titus MujuniAccounts Executive
<$5M
1-10
Private
-
-
N/A
<$5M
1-10
Private
-
-
N/A
Illustration of an envelope

Company Profile Activity

i

Among all Manufacturing companies

Low Activity

High Activity

Activity Insights

Tikosyn is experiencing very low activity levels compared to other companies in the Manufacturing sector.

What does this means?

Tikosyn is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tikosyn.

Top Manufacturing Companies

Frequently Asked Questions Regarding Tikosyn

What is Tikosyn's official website?
Tikosyn's official website is www.tikosyn.com
What is Tikosyn's Revenue?
Tikosyn's revenue is <$5 Million
What is Tikosyn's SIC code?
Tikosyn's SIC: 28,283
What is Tikosyn's NAICS code?
Tikosyn's NAICS: 32,325
How many employees does Tikosyn have?
Tikosyn has 11-50 employees
What industry does Tikosyn belong to?
Tikosyn is in the industry of: Manufacturing, Pharmaceuticals
What is Tikosyn competition?
Tikosyn top competitors include: Assertio Therapeutics, Brineura, Star Pharmaceuticals, Currax Pharmaceuticals
What does Tikosyn do?

Increase in QT interval is directly related to dofetilide dose and plasma concentration. Figure 1 shows that the relationship in normal volunteers between dofetilide plasma concentrations and change in QTc is linear, with a positive slope of approximately 1525 msec/(ng/mL) after the first dose and approximately 1015 msec/(ng/mL) at Day 23 (reflecti... ng a steady state of dosing). A linear relationship between mean QTc increase and dofetilide dose was also seen in patients with renal impairment, in patients with ischemic heart disease, and in patients with supraventricular and ventricular arrhythmias. Note: The range of dofetilide plasma concentrations achieved with the 500 mcg BID dose adjusted for creatinine clearance is 13.5 ng/mL. The relationship between dose, efficacy, and the increase in QTc from baseline at steady state for the two randomized, placebo-controlled studies (described further below) is shown in Figure 2. The studies examined the effectiveness of TIKOSYN in conversion to sinus rhythm and maintenance of normal sinus rhythm after conversion in patients with atrial fibrillation/flutter of 1 week duration. As shown, both the probability of a patient's remaining in sinus rhythm at six months and the change in QTc from baseline at steady state of dosing increased in an approximately linear fashion with increasing dose of TIKOSYN. Note that in these studies, doses were modified by results of creatinine clearance measurement and in-hospital QTc prolongation. Number of patients evaluated for maintenance of NSR: 503 TIKOSYN, 174 placebo. Number of patients evaluated for QTc change: 478 TIKOSYN, 167 placebo. Two randomized, parallel, double-blind, placebo-controlled, dose-response trials evaluated the ability of TIKOSYN 1) to convert patients with atrial fibrillation or atrial flutter (AF/AFl) of more than 1 week duration to normal sinus rhythm (NSR) and 2) to maintain NSR (delay time to recurrence of AF/AFl) after drug-induced or electrical cardioversion. A total of 996 patients with a one week to two ...Read More

Is Tikosyn a public company?
Tikosyn is private company therefore does not currently have an official ticker symbol
See more information about Tikosyn

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.